Submissions from 2024
Real-world outcomes in patients with biomarker-selected early-stage non-small cell lung cancer, Fawzi Abu Rous, Jesse Sussell, Celina Ngiam, Qing Zhang, Thomas Majda, Daniel Sheinson, Sarika Ogale, Ilze Bara, Katja Schulze, and Shirish M. Gadgeel
PP01.107 Patient Characteristics and Treatment Patterns in Biomarker Selected Early Non-Small Cell Lung Cancer, Fawzi Abu Rous, Jesse Sussell, Celina Ngiam Kochounian, Qing Zhang, Thomas Majda, Danny Sheinson, Sarika Ogale, Ilze Bara, and Shirish Gadgeel
Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial, Joachim Aerts, Luis G. Paz-Ares, Carole Helissey, Federico Cappuzzo, Gilles Quere, Dariusz Kowalski, Jose Carlos Benitez Sr., Florian Guisier, Benjamin Besse, Shirish M. Gadgeel, Thomas Wehler, Ignacio Gil-Bazo, Michael Jon Chisamore, Cem Gorgun, Ilhan Celik, Marie Holst Mørch, Patricia Garrido Castro, Teng Jin Ong, and Enriqueta Felip
A comprehensive analysis of the molecular landscape of HER3 expression in adenocarcinoma of the lung, S. K. Alhushki, A. N. Al-Bzour, N. N. Al-Bzour, H. M. Abushukair, and Fawzi Abu Rous
PP01.114 Outcomes of Patients Diagnosed with Lung Cancer after COVID-19 Infection, Zaid Al-Saheli, Omar Ammari, Linda Albusoul, Fawzi Abu Rous, and Shirish Gadgeel
The Polymerase Epsilon Gene Expression and Mutation Predictive Significance in Patients Receiving Immune Checkpoint Inhibitors (icis) for Non-small Cell Lung Cancer (NSCLS), A. Alshurafa, S. Alhushki, D. Alfaqheri, H. Abushukair, B. N. Alzghoul, and Fawzi Abu Rous
Black/African American participation in cancer clinical trials: A qualitative study of community members, patients with cancer, and survivors (Detroit, MI) using CBPR, Sylvester Antwi, Linda Kaljee, Doreen Dankerlui, Eleanor M. Walker, Harriet Larrious-Lartey, Barbara Brush, Barbara Israel, Donna Harris, Sophia Chue, Nayomi Cawthome, Cassandra Mills, Valerie Ofori Aboah, Gwendolyn Daniels, Livingstone Aduse-Poku, Chris M. Coombe, Zachary Rowe, La'Toshia Patman, Wayne Ramocan, Denise White-Perkins, and Evelyn M. Jiagge
Nuclear exporter protein exportin 1 (XPO1) as a novel therapeutic target in pancreatic neuroendocrine tumors, A. S. Azmi, M. H. Uddin, S. F. Bannoura, H. M. Khan, Maria Diab, S. Kim, E. Beal, M. Tobon, H. Chen, R. Beydoun, G. Dyson, R. M. Mohammad, Philip A. Philip, M. N. Al-Hallak, B. F. El-Rayes, and B. Pasche
EP.17B.03 Impact of Social Economic Status on Patient Reported Outcomes (PROs) In Non-Small Cell Lung Cancer (NSCLC), Julia L. Bachler, Anqi Wang, Laila Poisson, Eric Adjei Boakye, Samantha H. Tam, Shirish Gadgeel, Benjamin Movsas, and Bindu Potugari
EP.17B.03 Impact of Social Economic Status on Patient Reported Outcomes (PROs) In Non-Small Cell Lung Cancer (NSCLC), Julia L. Bachler, Anqi Wang, Laila M. Poisson, Eric Adjei Boakye, Samantha H. Tam, Shirish M. Gadgeel, Benjamin Movsas, and Bindu Potugari
1256MO Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours, B. Besse, A. E. Drilon, B. C. Cho, D. R. Camidge, J. Neal, C-C. Lin, S. V. Liu, M. Nagasaka, S. C-H Kao, E. Felip, A. J. Van Der Wekken, C. C. Lin, J. R. Bauman, Shirish Gadgeel, M. Samant, J. Shen, Y. Sun, V. W. Zhu, V. A. Upadhyay, and J. J. Lin
XMT-1660: A phase I, first-in-human trial of a B7-H4-directed dolasynthen antibody-drug conjugate in ovarian, endometrial, and breast cancers, Robert Burger, Erika Hamilton, Sylvia Adams, Hyo Han, Alexander Spira, Antonio Giordano, Arvind Chaudhry, Ritesh Parajuli, Judy Wang, Amy Weise, Nour Abuhadra, Patrick McNamara, and Kevin Kalinsky
XMT-1660: A phase I, first-in-human trial of a B7-H4-directed dolasynthen antibody-drug conjugate in ovarian, endometrial, and breast cancers, Robert Burger, Erika Hamilton, Sylvia Adams, Hyo Han, Alexander Spira, Antonio Giordano, Arvind Chaudhry, Ritesh Parajuli, Judy Wang, Amy Weise, Nour Abuhadra, Patrick McNamara, and Kevin Kalinsky
RGI-2001 with CNI-Based Prophylaxis Demonstrates Better Acute Gvhd-Free Survival Following Myeloablative Allohct without Increased Relapse: Comparison of a Multi-Center Phase 2b Study with a Contemporaneous CIBMTR Cohort, Yi-Bin Chen, Shatha Farhan, Lazaros J. Lekakis, Gary J. Schiller, Jean A. Yared, Markus Y. Mapara, Amer Assal, Hannah Choe, Zachariah DeFilipp, Dana D. Lee, Hayley Lane, Linda J. Burns, Mei-Jie Zhang, Matthew Bye, Ted A. Gooley, and Ayman Saad
Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1, A. C. Chiang, M. E. Olmedo Garcia, J. Carlisle, A. Dowlati, N. Reguart, E. Felip, P. J. Jost, N. Steeghs, R. Stec, Shirish Gadgeel, H. H. F Loong, W. Jiang, A. Hamidi, A. Parkes, and L. Paz-Ares
A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced HNSCC, Byoung Chul Cho, Omid Hamid, Xinhua Zhu, Bhumsuk Keam, John M. Kaczmar, Stephen K. Williamson, Ariel E. Birnbaum, Afshin Dowlati, Grace K. Dy, Steven Jeffrey Hager, Filipa Lynce, Raymond S. McDermott, Debashis Sarker, Amy M. Weise, Timothy A. Yap, Emrullah Yilmaz, Fang Fang, Jayakumar Mani, Glenn Scott Kroog, and Kyriakos P. Papadopoulos
Fractionated docetaxel (D) and radium 223 (Ra223) in metastatic castrationresistant prostate cancer (CRPC): A modular phase I trial, Brendan Connell, Clara Hwang, Edmund Folefac, Christian Lawlor, Benjamin Koethe, and Paul Mathew
HEALTHCARE-ASSOCIATED INFECTIONS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A NATIONWIDE ANALYSIS, John Cuenca, Bernard Moscoso, Diana Cardenas, Marissa Schettino, Daniel Gonzalez-Mosquera, Pool Tobar, Luis Gonzalez-Mosquera, and Joseph Nates
Pulsed low dose rate radiation to mitigate tumor-permissive responses in pancreatic cancer-associated fibroblasts: Introducing the HOST-factor, Edna Cukierman, Janusz Franco-Barraza, Tiffany Luong, Kristopher Raghavan, Jessica K. Wong, Débora Barbosa Vendramini Costa, Ralph Francescone, Jaye C. Gardiner, Sanjay S. Reddy, Elizabeth A. Handorf, and Joshua E. Meyer
PS3-3 Clinical and biomarker data from a phase 1/2 trial of ifinatamab deruxtecan (I-DXd; DS-7300) in advanced solid tumors, T. Doi, M. R. Patel, T. Koyama, G. S. Falchook, C. Friedman, S. A. Piha-Paul, M. Gutierrez, M. Awad, Ahmad Mattour, T. Satoh, S. Takahashi, T. Tsunoda, S. Kadowaki, Y. Watanabe, N. Okamoto, H. Goto, N. Yoshizuka, M. Qian, X. Qian, and M. Johnson
1253O Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours, A. E. Drilon, J. J. Lin, M. L. Johnson, C. S. Baik, L. G. Paz-Ares, B. Besse, J. Mazieres, A. Swalduz, A. R. Minchom, J. Reuss, Shirish Gadgeel, J. W. Riess, G. Liu, B. J. Solomon, D. R. Camidge, W. Swe, Y. Sun, J. Shen, V. W. Zhu, and E. Felip
Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial, Rafal Dziadziuszko, Fabrice Barlesi, Jeong Eun Kim, Shirish M. Gadgeel, Maciej Krzakowski, Jae Ho Jeong, Gennaro Daniele, David Chen, Youyou Hu, Timothy R. Wilson, Brian P. Simmons, and David M. Thomas
Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study, R. Dziadziuszko, S. Damian, Shirish Gadgeel, E. Garralda, A. Italiano, J. E. Kim, M. Krzakowski, C-C. Lin, A. Popovtzer, D. Thomas, W. Kirschbrown, S. Patel, T. Pham, M. Sbirnac, F. Wu, and F. Barlesi
STREAMLINING THE STUDY INTAKE PROCESS AT THE CANCER CLINICAL AND TRANSLATIONAL RESEARCH OFFICE (CCTRO), Raid Faddah, Tobias Walbert, James Snyder, Shirish Gadgeel, Philip A. Philip, and Lisa M. Lange
Irf3 and Irf7 induce epigenetic changes to promote pancreatic carcinogenesis, Lisa Fahr, Simone Benitz, Nicole Schreiner, Tobias Straub, Jurik Mutter, Hannah Hamidach, Ujjwal M. Mahajan, Georg Beyer, Katja Steiger, Andrea Terrasi, Gunnar Schotta, Axel Imhof, Kirsten Lauber, Jörg Kleeff, Christoph W. Michalski, Julia Mayerle, and Ivonne Regel
Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors, Tatyana Feldman, Enrica Marchi, Stephen D. Smith, Adam J. Olszewski, Auris O. Huen, Zachary D. Epstein-Peterson, Don A. Stevens, Alexander N. Starodub, Eric J. Feldman, Cristina P. Rodriguez, John C. Reneau, Jonathan E. Brammer, Ahmad H. Mattour, Lauren C. Pinter-Brown, Rachelle Perea, Patrick Henrick, Joyoti Dey, Alyssa Fasciano, Rahul Karnik, Sagar Agarwal, and Stefan K. Barta
Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study, Enriqueta Felip, Byoung Chul Cho, Vanesa Gutiérrez, Adlinda Alip, Benjamin Besse, Shun Lu, Alexander I. Spira, Nicolas Girard, Raffaele Califano, Shirish M. Gadgeel, James Chih-Hsin Yang, Naoyuki Nogami, Koichi Azuma, Joshua C. Curtin, Jiarui Zhang, Anesh Panchal, Mariah Ennis, Seema Niphadkar Sethi, Joshua Michael Bauml, and Se-Hoon Lee
689TiP A phase I/IIa trial of Aurora-A inhibitor (JAB-2485) in adult patients with advanced solid tumors, V. Florou, D. Orr, A. Morton, Y. Cheng, P. Yuan, Y. Sun, X. Tang, S. Liu, and Shirish Gadgeel
P3.12D.07 Divarasib Versus Adagrasib or Sotorasib in Pretreated KRAS G12C+ Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Shirish M. Gadgeel, A. Rahman, U. Osaghae, T. M. Fernando, M. T. Lin, K. Koli, C. Meyenberg, M. Mathisen, and F. Skoulidis
P3.12D.07 Divarasib Versus Adagrasib or Sotorasib in Pretreated KRAS G12C+ Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Shirish Gadgeel, A. Rahman, U. Osaghae, T. M. Fernando, M. T. Lin, K. Koli, C. Meyenberg, M. Mathisen, and F. Skoulidis
1813TiP Debio 0123, a highly selective WEE1 inhibitor, combined with carboplatin (CP) and etoposide (ETOP) in patients (pts) with small cell lung cancer (SCLC) that progressed after platinum-based therapy: A phase I dose escalation and expansion study, V. Gambardella, A. F. Navarro Mendivil, J. M. Lopez-Picazo Gonzalez, P. Jain, G. Fernandez-Hinojal, M. De Miguel, J. Zugazagoitia, Shirish Gadgeel, S. A. Bhatti, A. Vilalta, E. Castanon Alvarez, P. F. Simoes da Rocha, S. Micallef, R. Frederiksen Franzen, L. Piggott, A. Bellon, E. Rodrigo Imedio, and L. G. Paz-Ares
TIGIT expression increases with advancing clinical stages of resected pancreatic cancer, Madison George, Julie Clark, Kendyll Gartrelle, Georges Nassif, Kailee Hartway, Daniel Long, Daniel Salas-Escabillas, Allison Wombwell, Thais Pichardo, Hui-Ju Wen, Simone Benitz, Samuel Zwernik, Rupen Shah, Hakmin Park, Philip Philip, Gazala Khan, Howard Crawford, David Kwon, Brian Theisen, and Nina Steele
Longitudinal tissue-based evaluation of TIGIT expression in patients with pancreatic cancer: Effect of expression with advancing clinical stages and across racial groups, Madison George, Julie Clark, Kailee M. Hartway, Samuel Zwernik, Kendyll Gartrelle, Daniel Salas-Escabillas, Daniel Long, Georges Nassif, Thais Pichardo, Allison Wombwell, Hui-Ju Wen, Simone Benitz, Philip A. Philip, Gazala Khan, Rupen A. Shah, Hakmin Park, Howard C. Crawford, David S. Kwon, Brian Theisen, and Nina Steele
EP.13E.04 Racial Disparities in Genomic Subtypes of Small Cell Lung Cancer Patients, Manasi M. Godbole, Fawzi Abu Rous, Sunita Ghosh, Dhananjay Chitale, and Shirish Gadgeel
EP.13E.04 Racial Disparities in Genomic Subtypes of Small Cell Lung Cancer Patients, Manasi M. Godbole, Fawzi Abu Rous, Sunita Ghosh, Dhananjay Chitale, and Shirish M. Gadgeel
Factors influencing career choices and post-fellowship perspectives in adult hematology/oncology fellows: A nationwide cross-sectional study, Luis F. Gonzalez Mosquera, Nino Balanchivadze, Faria Ali, Matthew Meranda, Oscar Hinojosa Castro, and Philip Kuriakose
Abatacept with FluBu2: To Use or Not to Use, Luis F. Gonzalez-Mosquera, Klodiana Neme, Nancy Mikulandric, Izabela Mazur, Josephine Emole, Asif Alavi, Edward Peres, Muneer H. Abidi, and Shatha Farhan
The silent burden: A SEER-based analysis of potential years of life lost due to genitourinary cancers in the United States (1975-2017), Rajvi Gor, Pranav Gwalani, Dhairya Gor, Anand Shah, Rahul Kumar Thakur, and Benjamin Adam Gartrell
Pain, palliation, and opioid use patterns: A nationwide analysis of neoplasm-related pain admissions and trends (2016-2020), Rajvi Gor, Pranav Gwalani, Dhairya Gor, Anand Shah, Rahul Kumar Thakur, and Abhishek Kumar
PM2.5 and risk of lung cancer and associated mortality: An umbrella meta-analysis, Ashima Gupta, Abhishek Singh, Baris Tarimci, Alamjeet Kaur Sindhu, Pinank Bathvar, Simranjeet Bedi, Nyein Wint Yee Theik, Vedant Shah, Saarthak Malhotra, Milan Khealani, Sri Usha Jeevani Obulareddy, Geetika Kukreja, and Amaraja Kanitkar
Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises, Ashish O. Gupta, Akshay Sharma, Haydar Frangoul, Jignesh Dalal, Julie Kanter, Asif Alavi, John DiPersio, Mary Eapen, Jennifer J. Jaroscak, Ernesto Ayala, Edward D. Ziga, Stacey Rifkin-Zenenberg, Alex C. Minella, Guo Chen, Yinzhong Chen, Priya S. Chockalingam, Ling Lin, Marcelyne Joseney-Antoine, Leanne Ianniello, Beth Gardner, Adam J. Hartigan, Giuseppe Ciaramella, Sunita Goyal, Amy Simon, Alexis Thompson, and Matthew M. Heeney
NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA), Christopher Hanyoung Lieu, Guan Yu, Scott Kopetz, Shannon L. Puhalla, Peter C. Lucas, Ibrahim Halil Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, and Arvind Dasari
SPATIAL LOCALIZATION OF MACROPHAGES AND CANCER-ASSOCIATED FIBROBLASTS IN PANCREATIC CANCER: IMPLICATIONS FOR MYELOID TARGETING STRATEGIES, Natalie K. Horvat, Emily Greene, Alyssa Krasinskas, Maria Diab, Shishir Maithel, Juan Sarmiento, Olatunji Alese, and Gregory B. Lesinski
195MO Tarlatamab in previously treated small cell lung cancer (SCLC): DeLLphi-300 phase I study long-term outcomes and intracranial activity, H-D. Hummel, S. Champiat, M. E. Olmedo Garcia, M. Boyer, K. He, N. Steeghs, H. Izumi, M. L. Johnson, T. Yoshida, H. Bouchaab, A. Dowlati, H. Borghaei, E. Felip, P. J. Jost, Shirish Gadgeel, X. Chen, Y. Yu, P. Martinez, A. Parkes, and L. Paz-Ares
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3, Maen A. Hussein, Gazala Khan, Sreenivasa R. Chandana, Roberto A. Pazo Cid, Igor Kiss, Javier Gallego, Teresa Macarulla, Christelle De La Fouchardiere, Thorsten Goetze, Andrew Peter Dean, Eileen M. O'Reilly, Zev A. Wainberg, Woo Jin Lee, Eric Van Cutsem, Richard Hubner, Andrew S. Paulson, Tanios S. Bekaii-Saab, Shubham Pant, Fiona Maxwell, and Davide Melisi
1709P Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study, D. Kilari, A. Szabo, M. A. Bilen, Y. Ged, B. L. Maughan, Clara Hwang, H. McManus, P. M. Coelho Barata, A. Desai, Y. Zakharia, H. Emamekhoo, A. Tripathi, T. Rose, P. Ghatalia, M. A. Reimers, E. Heath, J. M. King, B. I. Rini, J. Brugarolas, and R. R. McKay
1965MO Phase II study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety, V. S. Koshkin, P. Barthelemy, G. Gravis, O. Goodman, I. Duran, R. Girones Sarrio, Clara Hwang, J. Garcia-Donas, R. Morales Barrera, S. Zanetta, M. Chisamore, M. Liu, M. Gil, G. Tomlinson, H. Elsayed, and Y. Loriot
Standard Risk Assessment Tools Fall Short to Assess Risk in Transplant Patients, Radhika Kulkarni, Luis F. Gonzalez, Chun-Hui Lin, Courtney Rose, Josephine Emole, Asif Alavi, Edward Peres, Muneer H. Abidi, and Shatha Farhan
Leukocyte immunoglobulin-like receptor (LILRB2)-targeted JTX-8064 plus the anti- PD1 inhibitor JTX-4014 (pimivalimab) in immune-checkpoint inhibitor (ICl) pretreated patients (pts) with advanced or metastatic renal cell cancer (mRCC): Results from the multi-stage phase 1-2 INNATE trial, Primo N. Lara Jr., Stew Kroll, Jonathan Alhaj Chatzkel, Deanna Gek Koon Teoh, Vincent T. Ma, Deepak Kilari, Clara Hwang, Randy F. Sweis, Kiran Yalamanchili, Julio A. Peguero, Tianhong Li, and Mamta Parikh
FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002), Xiuning Le, Alexander I. Spira, Shirish M. Gadgeel, Jonathan W. Riess, Yan Yu, Yanqiu Zhao, Ying Cheng, Oscar Juan-Vidal, Bo Gao, Kiyotaka Yoh, Martin Forster, Satoru Kitazono, Hidetoshi Hayashi, David Planchard, Yong Jiang, Nichole Baio, Marcin Kowanetz, William Leung, Jerry Y. Hsu, and Jie Wang
PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations, X. Le, Y. Yu, Y. Zhao, D. Planchard, Y. Cheng, X. Li, Shirish M. Gadgeel, J. Zhang, A. Spira, H. Hayashi, J. Riess, S. Kitazono, N. Leighl, B. Gao, O. Juan-Vidal, A. J. de Langen, J. Mazieres, M. Pérol, Y. Jiang, T. Hu, J. Huang, N. Baio, L. Musib, M. Kowanetz, S. Wang, W. Leung, S. Yea, J. Hsu, and J. Wang
PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations, X. Le, Y. Yu, Y. Zhao, D. Planchard, Y. Cheng, X. Li, Shirish Gadgeel, J. Zhang, A. Spira, H. Hayashi, J. Riess, S. Kitazono, N. Leighl, B. Gao, O. Juan-Vidal, A. J. de Langen, J. Mazieres, M. Pérol, Y. Jiang, T. Hu, J. Huang, N. Baio, L. Musib, M. Kowanetz, S. Wang, W. Leung, S. Yea, J. Hsu, and J. Wang
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%, Melissa Lynne Johnson, Edurne Arriola, Terufumi Kato, Nicolas Girard, Shirish M. Gadgeel, Jie Wang, Xia Li, Caitlin Lowery, Lee M. Krug, and Myung-Ju Ahn
1097P Long-term follow-up of advanced melanoma (unresectable/metastatic - aMel) patients (pts) treated with fianlimab (FIAN) + cemiplimab (CEMI): Results from blinded independent central review (BICR) efficacy assessment, M. Mckean, Amy M. Weise, K. P. Papadopoulos, J. P. Crown, S. S. Thomas, J. M. Mehnert, J. Kaczmar, K. B. Kim, N. J. Lakhani, M. L. Yushak, J. Mani, F. Fang, L. Brennan, I. Lowy, M. E. Salvati, M. G. Fury, K. Lewis, and O. Hamid
The Mediating Effects of Racial and Social Health Disparities on Cancer Urgent Care Outcomes: An Urban Cancer Center Experience, Matthew Meranda, Madison Drallmeier, Sisira Kavuri, Jamie Abad, Aayush Mittal, Rida Farook, Muniza Hossain, Courtney Rose, Carl P. Wilson, Muhammad Shahid, Philip Kuriakose, and Ahmad H. Mattour
MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSA, D. Nguyen, B. Besse, B. C. Cho, S.-H. Lee, K. H. Lee, S. Lu, Y. Cheng, Y. Yao, N. Girard, C.-C. Lin, E. Felip, A. Aguilar, C. Charoentum, F. J. S. M. Cruz, M. Majem, C. S. Lim, H. Akamatsu, H. Hayashi, J. C.-H. Yang, R. Kowalyszyn, K. Tiscoski, F. Franke, D. Ponomarenko, C. Arslan, M. Forster, D. Urban, D. Misch, A. Delmonte, L. V. G. Montes, Shirish M. Gadgeel, M. Cruz-Correa, J. Peguero, and S. Rousey
MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSA, D. Nguyen, B. Besse, B. C. Cho, S.-H. Lee, K. H. Lee, S. Lu, Y. Cheng, Y. Yao, N. Girard, C.-C. Lin, E. Felip, A. Aguilar, C. Charoentum, F. J./S./M Cruz, M. Majem, C. S. Lim, H. Akamatsu, H. Hayashi, J. C.-H Yang, R. Kowalyszyn, K. Tiscoski, F. Franke, D. Ponomarenko, C. Arslan, M. Forster, D. Urban, D. Misch, A. Delmonte, L. V./G Montes, Shirish M. Gadgeel, M. Cruz-Correa, J. Peguero, and S. Rousey
The Selective Personalized Radioimmunotherapy for Locally Advanced NSCLC Trial (SPRINT): Patient-Reported Outcomes, N. Ohri, S. Jolly, B. Cooper, R. Kabarriti, W. R. Bodner III, C. Guha, S. Viswanathan, E. Shum, J. K. Sabari, H. Cheng, R. Gucalp, E. Castellucci, A. Qin, Shirish M. Gadgeel, and B. Halmos
The Selective Personalized Radioimmunotherapy for Locally Advanced NSCLC Trial (SPRINT): Patient-Reported Outcomes, N. Ohri, S. Jolly, B. Cooper, R. Kabarriti, W. R. Bodner III, C. Guha, S. Viswanathan, E. Shum, J. K. Sabari, H. Cheng, R. Gucalp, E. Castellucci, A. Qin, Shirish M. Gadgeel, and B. Halmos
P1.13A.13 ALISertib in Patients with Extensive-Stage Small-Cell Lung Cancer: The Phase 2 ALISCA-Lung1 Study, Taofeek K. Owonikoko, T. F. Burns, Alberto A. Chiappori, B. Drapkin, Ryan D. Gentzler, J. Goldschmidt, D. Hakimian, R. Jotte, Stephen V. Liu, Adedayo A. Onitilo, Nathan A. Pennell, Bindu Potugari, J. Rios, Jacob Sands, A. Spira, Bo Wang, D. M. Waterhouse, Beth H. Lowenthal, Judith D. Bebchuk, Lisa DeFazio Eli, Elaine K. Wong, and Afshin Dowlati
P1.13A.13 ALISertib in Patients with Extensive-Stage Small-Cell Lung Cancer: The Phase 2 ALISCA-Lung1 Study, T. Owonikoko, T. F. Burns, A. A. Chiappori, B. Drapkin, R. D. Gentzler, J. Goldschmidt, D. Hakimian, R. Jotte, S. V. Liu, A. A. Onitilo, N. A. Pennell, Bindu Potugari, J. Rios, J. Sands, A. Spira, B. Wang, D. M. Waterhouse, B. Lowenthal, J. Bebchuk, L. D. Eli, E. K. Wong, and A. Dowlati
Association of tumor genetics with outcomes in patients (pts) with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA- 617, Justine Panian, Nicholas Henderson, Pedro C. Barata, Mehmet Asim Bilen, Laura Graham, Elisabeth I. Heath, Daniel Herchenhorn, Clara Hwang, Deepak Kilari, Vadim S. Koshkin, Jones T. Nauseef, Alexandra Sokolova, Yousef Zakharia, Michael T. Schweizer, Tanya B. Dorff, Andrew J. Armstrong, Ajjai S. Alva, and Rana R. McKay
Patient-reported and clinical outcomes among patients with pancreatic cancer, Rayli Pichardo, Brigid Jacob, Maria Jamil, Dawood Jamil, Shahm Raslan, Courtney M. Rose, Eric Adjei Boakye, Laila Poisson, Samantha Tam, and Philip A. Philip
Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors, Sarina A. Piha-Paul, Macarena Ines De La Fuente, Fabio Iwamoto, Seema Nagpal, Amy M. Weise, Jay-Jiguang Zhu, Sunandana Chandra, Chen Chen, Yali Fu, Zandong Yang, and Katy K. Tsai
Unfractionated Heparin Vs Enoxaparin Thromboprophylaxis in Medical-Surgical Patients: A Systematic Review and Meta-Analysis, Aakanksha Pitliya, Srivatsa S. Vasudevan, Vanshika Batra, Vishal Karmani, Anand Shah, Dhairya Gor, and Anmol Pitliya
P3.06D.12 Racial Differences in ALK Gene Alterations Detected by Tissue and Liquid Biopsy Across Patients with Lung Cancer, Bindu Potugari, Fawzi Abu Rous, Radhika Gutta, E. Teslow, C. Chao, E. Jaeger, and Shirish Gadgeel
P3.06D.12 Racial Differences in ALK Gene Alterations Detected by Tissue and Liquid Biopsy Across Patients with Lung Cancer, Bindu Potugari, Fawzi Abu Rous, Radhika Gutta, E. Teslow, C. Chao, E. Jaeger, and Shirish M. Gadgeel
Race and decisional conflict about genetic testing in patients with advanced prostate cancer, James P. Purtell, Avery Ralston, Courtney M. Rose, Kyle McElyea, Farhan Ibrahim, Alexandra Thompson, Sunita Ghosh, and Clara Hwang
Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT, Susana Rives, Giorgio Ottaviano, Nuria Martínez-Cibrián, Shatha Y. Farhan, Sowjanya Vuyyala, Jacques-Emmanuel Galimard, Eva Michel, Fizza Imran, Nazaret Sánchez-Sierra, Richard Mitchell, Stephan Mielke, Andishe Attarbaschi, Soeren Lykke Petersen, Ryhanen Samppa Sr., Wolfgang A. Bethge, David Beauvais, Tsila Zuckerman, Antonio Pérez-Martínez, Krzysztof Kalwak, Fabio Ciceri, Annalisa Ruggeri, Julio Delgado, Sebastian Giebel, Adriana Balduzzi, Anna Alonso-Saladrigues, and Valentin Ortiz-Maldonado
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL), M. Rizwan Rizwan-ul-Haq Khawaja, Abdul Rafeh Naqash, Reva Schneider, Aditi Shastri, Maximilian Stahl, Justin C. Moser, Nagla Fawzy Abdel Karim, Yazan Madanat, Brian A. Jonas, Eytan Stein, Shirish M. Gadgeel, James K. McCloskey, Ashwin Gollerkeri, Rachelle Perea, Yogesh Chutake, Sagar Agarwal, Patrick Henrick, Kelvin Shi, and Naval G. Daver
P3.12D.11 Phase 1/2, Dose-expansion Study of AMG 193, an MTA-cooperative PRMT5 Inhibitor, In MTAP-deleted NSCLC, A. Sacher, A. Addeo, T. Doi, Q. Chu, A. El Helali, L. Villaruz, H. Prenen, N. Vokes, J. Rodon, G. Durm, L. Lebellec, B. O’Neil, G. Dy, T. Eggert, K. Keyvanjah, and Shirish Gadgeel
P3.12D.11 Phase 1/2, Dose-expansion Study of AMG 193, an MTA-cooperative PRMT5 Inhibitor, In MTAP-deleted NSCLC, A. Sacher, A. Addeo, T. Doi, Q. Chu, A. El Helali, L. Villaruz, H. Prenen, N. Vokes, J. Rodon, G. Durm, L. Lebellec, B. O’Neil, G. Dy, T. Eggert, K. Keyvanjah, and Shirish M. Gadgeel
SWOG S2303: Randomized phase II/III trial of 2nd line nivolumab + paclitaxel + ramucirumab versus paclitaxel + ramucirumab in patients with PD-L1 CPS 1 advanced gastric and esophageal adenocarcinoma (PARAMUNE), Anwaar Saeed, Sarah Colby, Paul Eliezer Oberstein, Dan G. Duda, Rajiv Agarwal, Colmar Figueroa-Moseley, Riha Vaidya, Joseph M. Unger, Katherine A. Guthrie, Flavio G. Rocha, Maheswari Senthil, Rachael A. Safyan, Zev A. Wainberg, Syma Iqbal, E. Gabriela Chiorean, and Philip A. Philip
Diversity of patients enrolled in SWOG gastrointestinal cancers therapeutic trials, Rachael A. Safyan, Sarah Colby, Colmar Figueroa-Moseley, Katherine A. Guthrie, E. Gabriela Chiorean, and Philip A. Philip
Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9, Douglas W. Sborov, Charlotte Pawlyn, Tadao Ishida, Jeffrey S. Y. Huang, Reuben Benjamin, Shinsuke Iida, Rakesh Popat, Junya Kuroda, Matthew J. Pianko, Aravind Ramakrishnan, Steven R. Schuster, Vrushali S. Dabak, Alexander M. Lesokhin, Umberto Conte, Pooneh Soltantabar, Fangxin Hong, Erik Vandendries, and Rafael Fonseca
Lysine Demethylase 5a (Kdm5a) regulates metabolic activity and tumorigenic potential of murine pancreatic cancer cells, Nicole Schreiner, Lisa Fahr, Simone Benitz, Quan Zhou, Ahmed Alnatsha, Axel Imhof, Ujjwal Mahajan, Julia Mayerle, Gunnar Schotta, and Ivonne Regel
A Phase I/II Study of GDA-201, Cryopreserved Nicotinamide-Enhanced Allogeneic Natural Killer Cells, in Patients with Relapsed/Refractory B-Cell Lymphoma, Brian C. Shaffer, Matthew J. Frigault, Muhamad Alhaj Moustafa, Edward Peres, Stephanie B. Tsai, Stuart Levy, Yona Geffen, Roei Mazor, and Veronika Bachanova
Beyond the initial diagnosis: Epidemiological factors associated with second primary cancers among patients with head and neck squamous cell carcinoma (a SEER-based study), Anand Shah, Pranav Gwalani, Rajvi Gor, Dhairya Gor, Abiram Sivanandam, and Anupama H. Nehra
Evaluation and treatment response in patients with hormone receptor-positive, HER2 low metastatic breast cancer: A single center retrospective analysis, Muhammad A. Shahid, Radhika B. Kulkarni, Linda Albusoul, Brigid Jacob, Courtney M. Rose, Kylie Springer, and Vrushali S. Dabak
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer, Yan-Shen Shan, Chung-Pin Li, Gazala Khan, Woo Jin Lee, Hye Jin Choi, Heung-Moon Chang, Moon Hee Lee, John M. Wallmark, and Pei-Ni Chen
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer, Yan-Shen Shan, Chung-Pin Li, Gazala Khan, Woo Jin Lee, Hye Jin Choi, Heung-Moon Chang, Moon Hee Lee, John M. Wallmark, and Pei-Ni Chen
OA11.04 Volrustomig + platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update, D. R. Spigel, M.-J. Ahn, M. Majem, L. Medina Rodríguez, K. H. Lee, E. Carcereny, A. A. Hernández, A. Insa, E. K. Cho, B. Besse, S. Y. Rha, J. Weiss, M. D'Arcangelo, S.-A. Im, S.-W. Kim, B. A. Carneiro, Shirish M. Gadgeel, P. Mitchell, J. M. Asare, S. D. Gainer, I. Achour, D. S. Subramaniam, and E. Felip
OA11.04 Volrustomig + platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update, D. R. Spigel, M.-J. Ahn, M. Majem, L. Medina Rodríguez, K. H. Lee, E. Carcereny, A. A. Hernández, A. Insa, E. K. Cho, B. Besse, S. Y. Rha, J. Weiss, M. D'Arcangelo, S.-A. Im, S.-W. Kim, B. A. Carneiro, Shirish M. Gadgeel, P. Mitchell, J. M. Asare, S. D. Gainer, I. Achour, D. S. Subramaniam, and E. Felip
Real World Data on the Utility of P-Selectin Expression Assay; Correlation of Test Results and Disease Expression, Aroob Sweidan, Rachel L. Brancamp, Ileana Lopez-Plaza, Gordon Jacobsen, and Philip Kuriakose
1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC), B. Thapa, N. Henderson, S. T. Tagawa, Clara Hwang, A. O. Sokolova, M. A. Bilen, P. M. Coelho Barata, C. B. Nguyen, A. Tripathi, A. Ayanambakkam, L. S. Graham, Y. Zakharia, V. S. Koshkin, E. Heath, T. B. Dorff, A. J. Armstrong, R. R. McKay, A. S. Alva, M. Schweizer, and D. Kilari
Quantifying Tertiary Lymphoid Structures in Resected Pancreatic Ductal Adenocarcinoma in Clinical Practice - A Feasibility Study Demonstrating a Correlation with Survival, Brian K. Theisen, Madison George, Ian Loveless, and Nina Steele
Ipatasertib in patients with AKT1/2/3 mutation-positive (AKTmut) tumors: TAPISTRY study, David Thomas, Gennaro Daniele, Jeong Eun Kim, Shirish M. Gadgeel, Eugene R. Ahn, Luis G. Paz-Ares, Hans Prenen, David Chen, Junhan Fang, Timothy R. Wilson, Brian Simmons, and Fabrice Barlesi
PP01.69 Atypical Lung Carcinoids with EML4-ALK Fusion and Responses to ALK Inhibitors, Sarah Waliany, Yin P. Hung, Fawzi Abu Rous, Andrew Do, Jennifer Peterson, Caitlin Meservey, Subba R. Digumarthy, Shirish M. Gadgeel, Jessica J. Lin, and Catherine B. Meador
Upstaging from cT1 to pT2 in Triple Negative and Her2 Positive Breast Cancer: an Opportunity to Identify cT1 Breast Cancer Patients for whom Neoadjuvant Chemotherapy Should be Considered, Rachel Wobig, Jessica M. Bensenhaver, Hemi Thaker, Christine Joliat, Theresa L. Schwartz, Anna V. Lehrberg, Laura K. Dalla Vecchia, Saul D. Nathanson, Laura L. Susick, Kylie Springer, Lindsay F. Petersen, and Haythem Ali
Engraftment Day Electrolytes and Hydration and the Risk of Atrial Fibrillation Early after Hematopoietic Stem Cell Transplant, Min Wu, Adnan Khan, Edward Peres, Josephine Emole, Asif Alavi, Muneer H. Abidi, Madhulata Reddy, and Shatha Farhan
The impact of SPOP gene alterations in men with metastatic prostate cancer: Results from the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) consortium, Kyra L. Yamamoto, Nicholas Henderson, Clara Hwang, Pedro C. Barata, Mehmet A. Bilen, Deepak Kilari, Laura Graham, Rohan Garje, Shoshana Rothstein, Vadim S. Koshkin, Abhishek Tripathi, Frank C. Cackowski, Jones T. Nauseef, Michael T. Schweizer, Andrew J. Armstrong, Tanya B. Dorff, Ajjai S. Alva, and Rana R. McKay
DRAGON TRIAL: DURABLE REMISSION RATE WITH THE LATENT TGFb1 INHIBITOR LINAVONKIBART (SRK-181) AND PEMBROLIZUMAB IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR RESISTANT ADVANCED CANCERS, Timothy A. Yap, Randy Sweis, Ulka N. Vaishampayan, Deepak Kilari, Ahmad A. Tarhini, Justin F. Gainor, Minal Barve, Guru P. Sonpavde, David Park, Sunil Babu, Rana McKay, Clara Hwang, Amna Sher, Chaitali Nangia, Miso Kim, Jungyoon Choi, Yawen Ju, Lan Liu, Susan Henry, Stephen DeWall, and Lu Gan
A phase 2 clinical trial of first-in-class fascin inhibitor NP-G2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies, Frank Yung-Chin Tsai, Michael J. Birrer, Jason R. Brown, Sanjay Chandrasekaran, Vincent Chung, Richard C. Frank, Edward G. Garmey, Shirish M. Gadgeel, Thomas J. George, Shadia I. Jalal, Andrew S. Poklepovic, Jennifer M. Segar, Alexander I. Spira, Jue J. Zhang, and Anup Kasi
Outcomes of Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax: A Single Institution Analysis, Markie Zimmer, Brigid Jacob, Mikayla Spica, Sunita Ghosh, and Vrushali S. Dabak
Submissions from 2023
THE ASSOCIATION BETWEEN MESOTHELIAL MEMBRANES METASTASIS AND RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN SOLID TUMORS, Hassan Abushukair, Constantine Logothetis, Fawzi Abu Rous, Anwaar Saeed, Olivia Aranha, and Moh’d Khushman5
Trend in Von Willebrand Factor Profile in Women With Von Willebrand Disease During Pregnancy and Postpartum, Linda Albusoul, Muhammad Shahid, Sowjanya Vuyyala, Zaher K. Otrock, and Philip Kuriakose
EP03.03-02 Multi-omics Analysis of Immune Determinants of STK11 in Non-Small Cell Lung Cancer, S. K. Alhushki, A. Al-Muhtaseb, H. Abushukair, and Fawzi Abu Rous
Implementing Quality Improvement to Morbidity and Mortality Conferences: Focusing on Action Plans By Closing the Loops with Timely Follow Ups, Zaid Al-Saheli and Vijaya Donthireddy
Molecular characterization and clinical outcomes of pancreatic neuroendocrine tumors (pNENs) harboring PAK4-NAMPT alterations, Ibrahim Azar, Nishant Gandhi, Misako Nagasaka, Jun Gong, Bassel Nazha, Khalil Choucair, Moh'd M. Khushman, Heloisa P. Soares, Wafik S. El-Deiry, Philip A. Philip, Emil Lou, Alex P. Farrell, Jeffrey Swensen, Matthew J. Oberley, Jim Abraham, Chadi Nabhan, Sanjay Goel, Wolfgang M. Korn, and Anthony F. Shields
P-76 Genomic and transcriptomic characterization of pancreatic neuroendocrine tumors reveals novel therapeutic candidates, A. Azmi, Z. Mahdi, S. Bannoura, M. Al-Hallak, M. Uddin, H. Khan, I. Muqbil, R. Mohammad, H. Chen, Philip A. Philip, and B. El-Rayes
